Antibodies that obstruct immune checkpoints, namely Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and PD-1/PD-L1, have proven highly successful in cancer immunotherapy. Here, CTLA4 is linked to cancer.